Opus Genetics, Inc. (NASDAQ:IRD)
| Market Cap | 473.10M+330.8% |
| Revenue (ttm) | 9.86M-36.1% |
| Net Income | -107.61M-84.7% |
| EPS | -1.27+27.8% |
| Shares Out | 82.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,753,766 |
| Open | 5.33 |
| Previous Close | 4.34 |
| Day's Range | 5.32 - 7.07 |
| 52-Week Range | 1.32 - 7.07 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 12.00(+109.42%) |
| Earnings Date | Nov 11, 2026 |
About IRD
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IRD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IRD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IRD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IRD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IRD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IRD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IRD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $8.31M |
| IWMiShares Russell 2000 ETF | $6.37M |
| VXFVanguard Extended Market ETF | $2.42M |
| IWOiShares Russell 2000 Growth ETF | $2.30M |
| VTWOVanguard Russell 2000 ETF | $1.11M |
| IWCiShares Micro-Cap ETF | $845.02K |
Estimated from each fund’s disclosed top holdings × AUM
IRD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IRD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score